公开(公告)号：US12103955B2

公开(公告)日：2024-10-01

申请号：US16944014

申请日：2020-07-30

Applicant: MODERNATX, INC.

Inventor： Barry Ticho ,  Nadege Briancon-Eris ,  Zhinan Xia ,  Athanasios Dousis ,  Seymour de Picciotto ,  Vladimir Presnyak ,  Stephen Hoge ,  Iain Mcfadyen ,  Kerry Benenato ,  Ellalahewage Sathyajith Kumarasinghe

IPC: C12N15/62 ,  A61K31/7105 ,  A61K38/17 ,  A61K47/14 ,  A61K47/69 ,  A61K48/00 ,  A61P9/00 ,  C07K14/64 ,  C07K16/26 ,  C12N15/52 ,  A61K9/00 ,  A61K9/127 ,  A61K38/00

CPC classification number: C07K14/64 ,  A61K31/7105 ,  A61K38/1796 ,  A61K47/6929 ,  A61P9/00 ,  C07K16/26 ,  C12N15/52 ,  C12N15/62 ,  A61K9/0019 ,  A61K9/127 ,  A61K38/00 ,  C07K2319/00 ,  C07K2319/31

Abstract: The invention relates to mRNA therapy for the treatment of fibrosis and/or cardiovascular disease. mRNAs for use in the invention, when administered in vivo, encode human relaxin, isoforms thereof, functional fragments thereof, and fusion proteins comprising relaxin. mRNAs of the invention are preferably encapsulated in lipid nanoparticles (LNPs) to effect efficient delivery to cells and/or tissues in subjects, when administered thereto. mRNA therapies of the invention increase and/or restore deficient levels of relaxin expression and/or activity in subjects. mRNA therapies of the invention further decrease levels of toxic metabolites associated with deficient relaxin activity in subjects.

公开(公告)号：US10730924B2

公开(公告)日：2020-08-04

申请号：US16025302

申请日：2018-07-02

Applicant: ModernaTX, Inc.

Inventor： Barry Ticho ,  Nadege Briancon-Eris ,  Zhinan Xia ,  Athanasios Dousis ,  Seymour de Picciotto ,  Vladimir Presnyak ,  Stephen Hoge ,  Iain Mcfadyen ,  Kerry Benenato ,  Ellalahewage Sathyajith Kumarasinghe

IPC: C12N15/62 ,  A61K47/14 ,  C07K14/64 ,  A61K31/7105 ,  A61K47/69 ,  A61P9/00 ,  A61K38/17 ,  C07K16/26 ,  C12N15/52 ,  A61K9/127 ,  A61K38/00 ,  A61K9/00

Abstract: The invention relates to mRNA therapy for the treatment of fibrosis and/or cardiovascular disease. mRNAs for use in the invention, when administered in vivo, encode human relaxin, isoforms thereof, functional fragments thereof, and fusion proteins comprising relaxin. mRNAs of the invention are preferably encapsulated in lipid nanoparticles (LNPs) to effect efficient delivery to cells and/or tissues in subjects, when administered thereto. mRNA therapies of the invention increase and/or restore deficient levels of relaxin expression and/or activity in subjects. mRNA therapies of the invention further decrease levels of toxic metabolites associated with deficient relaxin activity in subjects.

公开(公告)号：US20180371047A1

公开(公告)日：2018-12-27

申请号：US16025302

申请日：2018-07-02

Applicant: ModernaTX, Inc.

Inventor： Barry Ticho ,  Nadege Briancon-Eris ,  Zhinan Xia ,  Athanasios Dousis ,  Seymour de Picciotto ,  Vladimir Presnyak ,  Stephen Hoge ,  Iain Mcfadyen ,  Kerry Benenato ,  Ellalahewage Sathyajith Kumarasinghe

IPC: C07K14/64 ,  A61P9/00 ,  C12N15/62 ,  C12N15/52 ,  A61K47/69 ,  C07K16/26 ,  A61K38/17

Abstract: The invention relates to mRNA therapy for the treatment of fibrosis and/or cardiovascular disease. mRNAs for use in the invention, when administered in vivo, encode human relaxin, isoforms thereof, functional fragments thereof, and fusion proteins comprising relaxin. mRNAs of the invention are preferably encapsulated in lipid nanoparticles (LNPs) to effect efficient delivery to cells and/or tissues in subjects, when administered thereto. mRNA therapies of the invention increase and/or restore deficient levels of relaxin expression and/or activity in subjects. mRNA therapies of the invention further decrease levels of toxic metabolites associated with deficient relaxin activity in subjects.